| . | CD47 . | . | |
|---|---|---|---|
| Clinicopathological parameters . | Negative (n = 62) . | Positive (n = 36) . | P value . |
| Age (32–83 yr) | 55 ± 11 | 58 ± 13 | 0.2448 |
| Menopausal status | |||
| Pre | 27 | 11 | 0.2032 |
| Post | 35 | 25 | |
| Nuclear grade | |||
| 1 | 23 | 12 | 0.7615 |
| 2 | 36 | 21 | |
| 3 | 3 | 3 | |
| Lymphatic duct invasion | |||
| − | 48 | 19 | 0.0115 |
| + | 14 | 17 | |
| Vascular invasion | |||
| − | 44 | 10 | <0.0001 |
| + | 18 | 26 | |
| Pathological T | |||
| T1 | 54 | 27 | 0.0797 |
| T2 | 6 | 9 | |
| T3 | 2 | 0 | |
| LN metastasis | |||
| − | 18 | 15 | 0.2221 |
| + | 43 | 21 | |
| Pathological stage | |||
| I | 38 | 17 | 0.1286 |
| II | 19 | 18 | |
| III | 5 | 1 | |
| ER | |||
| − | 10 | 7 | 0.6760 |
| + | 52 | 29 | |
| PR | |||
| − | 15 | 11 | 0.4916 |
| + | 47 | 25 | |
| HER2 | |||
| − | 9 | 7 | 0.5246 |
| + | 53 | 29 | |
| HLA-G | 0.0094 | ||
| Low | 44 | 16 | |
| High | 18 | 20 | |
| Treatment (FEC ± DOC) | |||
| − | 56 | 35 | 0.2011 |
| + | 6 | 1 | |
| . | CD47 . | . | |
|---|---|---|---|
| Clinicopathological parameters . | Negative (n = 62) . | Positive (n = 36) . | P value . |
| Age (32–83 yr) | 55 ± 11 | 58 ± 13 | 0.2448 |
| Menopausal status | |||
| Pre | 27 | 11 | 0.2032 |
| Post | 35 | 25 | |
| Nuclear grade | |||
| 1 | 23 | 12 | 0.7615 |
| 2 | 36 | 21 | |
| 3 | 3 | 3 | |
| Lymphatic duct invasion | |||
| − | 48 | 19 | 0.0115 |
| + | 14 | 17 | |
| Vascular invasion | |||
| − | 44 | 10 | <0.0001 |
| + | 18 | 26 | |
| Pathological T | |||
| T1 | 54 | 27 | 0.0797 |
| T2 | 6 | 9 | |
| T3 | 2 | 0 | |
| LN metastasis | |||
| − | 18 | 15 | 0.2221 |
| + | 43 | 21 | |
| Pathological stage | |||
| I | 38 | 17 | 0.1286 |
| II | 19 | 18 | |
| III | 5 | 1 | |
| ER | |||
| − | 10 | 7 | 0.6760 |
| + | 52 | 29 | |
| PR | |||
| − | 15 | 11 | 0.4916 |
| + | 47 | 25 | |
| HER2 | |||
| − | 9 | 7 | 0.5246 |
| + | 53 | 29 | |
| HLA-G | 0.0094 | ||
| Low | 44 | 16 | |
| High | 18 | 20 | |
| Treatment (FEC ± DOC) | |||
| − | 56 | 35 | 0.2011 |
| + | 6 | 1 | |
DOC, docetaxel; FEC, 5-fluorouracil, epirubicin, and cyclophosphamide. P < 0.05 was considered statistically significant.